• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Scan suspected stroke patients within 1 hour, says RCP
Royal College of Physicians launches new guidance Related items fromOnMedica Stroke patients still not getting care they need NHS stroke care getting better NICE wants GPs to prevent 8,000 strokes a year Aspirin after mini-stroke reduces risk of major stroke Stroke can often be avoided, claims study
Source: OnMedica Latest News - October 4, 2016 Category: UK Health Source Type: news

NICE advises against aspirin for cutting stroke risk in AF patients
The National Institute for Health and Care Excellence has recommended that people with atrial fibrillation are prescribed an anticoagulant instead of aspirin to reduce their risk of stroke.
Source: Nursing Times Breaking News - June 20, 2014 Category: Nursing Source Type: news

Aspirin too risky for stroke patients, NICE says
Adults with atrial fibrillation (AF) should no longer be prescribed aspirin to prevent stroke, NICE guidance released today said Hide related content:  Show related content read more
Source: Management in Practice - July 10, 2015 Category: Practice Management Authors: ltrevallion Tags: *** Editor ' s Pick Latest News Source Type: news

NICE recommends anticoagulants over aspirin for stroke prevention
AF is a condition that affects the heart, causing it to beat irregularly and too fast. When this happens, blood does not flow properly through the heart and the rest of the body. NICE’s latest quality standard, which sets out advice on the treatment and management of AF,  recommends that people with AF who have a CHA2DS2-VASC stroke risk score of 2 or above are offered newer anticoagulants, such as apixaban, dabigatran etexilate, rivaroxaban or a vitamin K antagonist like warfarin.
Source: NHS Networks - July 10, 2015 Category: UK Health Authors: Maria Axford Source Type: news

From Bermuda to Boston for surgery to protect the brain of a boy with sickle cell disease
Calvin Steede, who lives in Bermuda, will never forget the day in 2011 when he saw the movie “Winnie the Pooh” with his mother and sister. The film ended, and suddenly the boy who likes to draw and play soccer couldn’t put on his backpack. His arms had stopped working. He couldn’t stand, and soon he couldn’t talk. Calvin, now 11, had suffered a minor stroke, a complication of sickle cell disease and the first step of a journey that would take him to Dana-Farber/Boston Children’s Cancer and Blood Disorders Center for minimally invasive surgery to protect his brain from future strokes. Sickle cell disease Sickle ...
Source: Thrive, Children's Hospital Boston - June 19, 2015 Category: Pediatrics Authors: Irene Sege Tags: Diseases & conditions Dana-Farber/Boston Children's Cancer and Blood Disorders Center moyamoya sickle cell disease Source Type: news

Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Abstract As part of its Single Technology Appraisal process, the National Institute for Health and Care Excellence (NICE) invited the company that manufactures rivaroxaban (Xarelto, Bayer) to submit evidence of the clinical and cost effectiveness of rivaroxaban for the prevention of adverse outcomes in patients after the acute management of acute coronary syndrome (ACS). The School of Health and Related Research Technology Appraisal Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group (ERG). The ERG produced a critical review of the evidence for the clinical and cos...
Source: PharmacoEconomics - December 21, 2015 Category: Health Management Source Type: research

Heparin, grad students, a clinical revolution and giving credit where it's due
The story of a grad student who overcame remarkable odds only to be denied his moment of glory, or a tale of dark deceit and devilish doings? The story of heparin is as complicated as the chemistry itselfBlood is remarkable.A liquid that carries nutrients, waste products and the ever-vigilant cells of the immune system around the body, blood rapidly turns into a solid when it leaves its veins and arteries and becomes exposed to bodily tissues or the air outside. This process of solidification – clotting, or coagulation – is executed and controlled by a complex set of reactions and interactions primarily involving the e...
Source: Guardian Unlimited Science - September 4, 2013 Category: Science Authors: Richard P Grant Tags: theguardian.com Blogposts Science Source Type: news

GPs to review aspirin use in atrial fibrillation patients
NICE calls for increased uptake of anticoagulantsRelated items from OnMedicaAlteplase use linked to reduction in disability after strokeGPs should screen over 65s for atrial fibrillationAtrial fibrillation raises risk of cognitive problems Statin use after stroke not linked to bleedsNew guidance to prevent strokes
Source: OnMedica Latest News - June 19, 2014 Category: UK Health Source Type: news

NICE recommends more INR self-monitoring
Quicker dose adjustment will result in fewer major bleeds, MIs and strokes, says guidanceRelated items from OnMedicaHuge benefits to new anti-clotting drugAspirin as effective as warfarin for heart patientsDaily aspirin use linked to major bleedingStatin use after stroke not linked to bleedsSelf-monitoring cuts warfarin clot risk
Source: OnMedica Latest News - September 25, 2014 Category: UK Health Source Type: news

Arguments favoring low versus high dose aspirin in the prophylaxis of venous thromboembolism
The use of aspirin in the prevention of venous thromboembolism (VTE) is still controversial. In a profound review on the use of aspirin for primary and secondary prevention of venous thromboembolism and other cardiovascular disorders Cohen et al. [1] conclude that the benefits of aspirin are well documented for conditions like myocardial infarction, coronary heart disease, and stroke, but less clearly for prevention of VTE after orthopedic surgery. The latter indistinctness has been a matter of concern in many earlier reviews and meta-analyses, and has even led to non-uniform guidelines on VTE prevention from the American ...
Source: Thrombosis Research - January 27, 2016 Category: Hematology Authors: Piet Borgdorff, Geert Jan Tangelder Tags: Correspondence Source Type: research

Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
AbstractThe National Institute for Health and Care Excellence (NICE) invited AstraZeneca, the manufacturer of ticagrelor (Brilique®), to submit evidence on the clinical and cost effectiveness of ticagrelor 60  mg twice daily (BID) in combination with low-dose aspirin [acetylsalicylic acid (ASA)] compared with ASA only for secondary prevention of atherothrombotic events in patients with a history of myocardial infarction (MI) and who are at increased risk of atherothrombotic events. Kleijnen Systematic R eviews Ltd (KSR), in collaboration with Maastricht University Medical Centre+, was commissioned as the evidence review ...
Source: PharmacoEconomics - January 18, 2018 Category: Health Management Source Type: research